We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+18.27%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$715M
AUM Growth
+$146M
Cap. Flow
+$89.1M
Cap. Flow %
12.46%
Top 10 Hldgs %
60.6%
Holding
38
New
7
Increased
10
Reduced
4
Closed
3

Top Buys

Rank Stock Value
1
DNTH icon
Dianthus Therapeutics
DNTH
+$28.7M
2
BPMC
Blueprint Medicines
BPMC
+$22.8M
3
FMI
Foundation Medicine, Inc.
FMI
+$15M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$10.7M
5
BLUE
bluebird bio
BLUE
+$9.68M

Top Sells

Rank Stock Value
1
EVH icon
Evolent Health
EVH
+$10.6M
2
IBB icon
iShares Biotechnology ETF
IBB
+$10.1M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$5.46M
4
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$3.75M
5
GNMK
GenMark Diagnostics, Inc
GNMK
+$2.97M

Sector Composition

Rank Sector Weight
1 Healthcare 90.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FMI
1
DELISTED
Foundation Medicine, Inc.
FMI
$93.6M 13.1%
685,000
+165,000
+32% +$15M
LOXO
2
DELISTED
Loxo Oncology, Inc
LOXO
$62.5M 8.73%
360,000
– –
BPMC
3
DELISTED
Blueprint Medicines
BPMC
$40.3M 5.64%
635,000
+287,000
+82% +$22.8M
SAGE
4
DELISTED
Sage Therapeutics
SAGE
$39.1M 5.47%
250,000
– –
MYOK
5
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$38.7M 5.42%
780,000
+220,000
+39% +$10.7M
ONCE
6
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$38.3M 5.36%
463,000
– –
BLUE
7
DELISTED
bluebird bio
BLUE
$31.4M 4.39%
15,440
+4,246
+38% +$9.68M
AGIO icon
8
Agios Pharmaceuticals
AGIO
$1.84B
$30.7M 4.3%
364,776
– –
FATE icon
9
Fate Therapeutics
FATE
$294M
$29.5M 4.12%
2,600,000
– –
CDXS icon
10
Codexis
CDXS
$158M
$29.2M 4.08%
2,025,000
– –
DNTH icon
11
Dianthus Therapeutics
DNTH
$5.72B
$27.5M 3.84%
+127,239
New +$28.7M
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$29.1B
$26.6M 3.72%
270,000
+20,000
+8% +$1.98M
VYGR icon
13
Voyager Therapeutics
VYGR
$179M
$22.2M 3.1%
1,135,000
– –
GBT
14
DELISTED
Global Blood Therapeutics, Inc.
GBT
$21.7M 3.03%
480,000
-120,000
-20% -$5.46M
GNMK
15
DELISTED
GenMark Diagnostics, Inc
GNMK
$21.7M 3.03%
3,400,000
-450,000
-12% -$2.97M
ILMN icon
16
Illumina
ILMN
$30.2B
$20M 2.79%
73,502
– –
SGMO
17
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$19.9M 2.78%
1,400,000
– –
BOLD
18
DELISTED
Audentes Therapeutics, Inc
BOLD
$17.2M 2.4%
450,000
– –
CRSP icon
19
CRISPR Therapeutics
CRSP
$4.86B
$12.9M 1.81%
220,000
+85,000
+63% +$4.84M
EVH icon
20
Evolent Health
EVH
$359M
$11.6M 1.62%
550,000
-560,000
-50% -$10.6M
BLFS icon
21
BioLife Solutions
BLFS
$1.56B
$11.4M 1.6%
+1,000,000
New +$9.1M
ONC
22
BeOne Medicines Ltd
ONC
$32.3B
$10.8M 1.51%
70,000
– –
OSUR icon
23
OraSure Technologies
OSUR
$286M
$10.5M 1.47%
640,000
+400,000
+167% +$6.75M
CLVS
24
DELISTED
Clovis Oncology, Inc.
CLVS
$10M 1.4%
220,000
+42,500
+24% +$2.07M
EDIT icon
25
Editas Medicine
EDIT
$399M
$6.39M 0.89%
178,333
+45,000
+34% +$1.59M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q2 2018 Portfolio in Review

As of Q2 2018, Casdin Capital held 38 positions worth $715M, up 26% from $569M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Casdin Capital deployed $89.1M of net new capital in Q2 2018, opening 7 new positions and adding to 10 existing holdings. Its largest new stake was Dianthus Therapeutics: 127,239 shares worth $27.5M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier.

On the sell side, the largest reduction was Evolent Health, an estimated $10.6M trimmed.

  • Casdin Capital's largest Q2 2018 buy was Dianthus Therapeutics: 127,239 shares worth $27.5M.
  • Casdin Capital added most to Blueprint Medicines in Q2 2018, an estimated $22.8M increase.
  • Casdin Capital's biggest Q2 2018 reduction was Evolent Health, cutting an estimated $10.6M.
  • Casdin Capital fully exited iShares Biotechnology ETF in Q2 2018, selling an estimated $10.1M.
  • Casdin Capital's ten largest holdings make up 61% of its $715M portfolio in Q2 2018.
  • Casdin Capital opened 7 new positions and closed 3 in Q2 2018.
  • Casdin Capital's portfolio value rose 26% quarter-over-quarter to $715M.

Based on Casdin Capital's 13F filing for Q2 2018, filed 14 Aug 2018.